PMV Pharmaceuticals Future Growth
Future criteria checks 0/6
PMV Pharmaceuticals's earnings are forecast to decline at 0.7% per annum while its annual revenue is expected to grow at 70.6% per year. EPS is expected to grow by 2.3% per annum.
Key information
-0.7%
Earnings growth rate
2.3%
EPS growth rate
| Biotechs earnings growth | 27.6% |
| Revenue growth rate | 70.6% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 13 Nov 2024 |
Recent future growth updates
Recent updates
Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?
Aug 04
Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Apr 20Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Dec 22We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth
Sep 08Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation
May 10PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans
Jan 11Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Sep 22PMV Pharmaceuticals GAAP EPS of -$0.38 beats by $0.04
Aug 09PMV Pharma joins Merck to study lead candidate with Keytruda
Jul 18Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Jun 09Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation
Feb 23Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Nov 05Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation
Jul 23PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Strong Position To Grow Its Business
Apr 09Do Institutions Own PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares?
Dec 25PMV Pharmaceuticals reports Q3 results
Nov 13Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -95 | -84 | N/A | 4 |
| 12/31/2025 | N/A | -84 | -76 | N/A | 6 |
| 12/31/2024 | N/A | -59 | -76 | N/A | 6 |
| 9/30/2024 | N/A | -51 | -48 | -47 | N/A |
| 6/30/2024 | N/A | -49 | -46 | -46 | N/A |
| 3/31/2024 | N/A | -65 | -58 | -57 | N/A |
| 12/31/2023 | N/A | -69 | -57 | -56 | N/A |
| 9/30/2023 | N/A | -73 | -61 | -59 | N/A |
| 6/30/2023 | N/A | -74 | -64 | -60 | N/A |
| 3/31/2023 | N/A | -74 | -68 | -61 | N/A |
| 12/31/2022 | N/A | -73 | -72 | -64 | N/A |
| 9/30/2022 | N/A | -72 | -67 | -60 | N/A |
| 6/30/2022 | N/A | -69 | -61 | -56 | N/A |
| 3/31/2022 | N/A | -65 | -54 | -52 | N/A |
| 12/31/2021 | N/A | -58 | -48 | -47 | N/A |
| 9/30/2021 | N/A | -50 | -46 | -45 | N/A |
| 6/30/2021 | N/A | -44 | -41 | -40 | N/A |
| 3/31/2021 | N/A | -39 | -38 | -38 | N/A |
| 12/31/2020 | N/A | -34 | -33 | -33 | N/A |
| 9/30/2020 | N/A | -31 | -28 | -28 | N/A |
| 6/30/2020 | N/A | -28 | -26 | -26 | N/A |
| 3/31/2020 | N/A | -27 | -25 | -25 | N/A |
| 12/31/2019 | N/A | -25 | -22 | -22 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PMVP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PMVP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PMVP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PMVP is forecast to have no revenue next year.
High Growth Revenue: PMVP is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PMVP's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 19:44 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PMV Pharmaceuticals, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Harrison | BofA Global Research |
| Gum-Ming Lowe | Craig-Hallum Capital Group LLC |
| Joshua Schimmer | Evercore ISI |